AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01657786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of ondanstron and screening of genomic DNA
Description: Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
Study NCT02497248 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein ablation
Description: Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
Study NCT00488332 — intervention group
Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Before radiation treatment and once a week thereafter.
Study NCT00488332 — intervention group
Intervention type: PROCEDURE
Intervention: Fluorescence Spectroscopy
Description: Before radiation treatment and once a week thereafter.
Study NCT00488332 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain Scale Questionnaire
Description: Administered before the examination, OCT, and FS and immediately afterward.
Study NCT03590366 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: B244 Suspension
Study NCT02766647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira (US)
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
Study NCT03590366 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study NCT02958631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Study NCT02958631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT00721149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
Study NCT04449120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet-based culinary intervention
Description: The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
Study NCT04449120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet-based nutritional education intervention
Description: The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
Study NCT03806101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 200 mg dose of PF-04965842 once daily (QD) for 3 days
Study NCT03806101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single 10 mg dose of rosuvastatin
Study NCT04064073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: Tablets, Oral, once daily single dose
Study NCT02766647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US-approved Neupogen®
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
Study NCT02184819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: 24 hour continuous infusion at the rate of 0,1 µg/kg/min
Study NCT02184819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
Study NCT00161213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00161213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT04149340 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cataract surgery
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
Study NCT04149340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cataract surgery
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
Study NCT05402709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior mobilisation technique
Description: Posterior mobilisation technique were applied
Study NCT05402709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior capsule stretching
Description: Posterior capsule stretching were applied
Study NCT01009593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
Study NCT01009593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
Study NCT02198534 — intervention group
Intervention type: DEVICE
Intervention: Methodology of visual acuity assessment
Study NCT01506856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel(intravenous) + Carboplatin(intravenous)
Description: Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
Study NCT01506856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Description: Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
Study NCT01266616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Profectus HIV MAG pDNA vaccine
Description: 3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
Study NCT01266616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Administered at Weeks 0, 4, and 12
Study NCT01266616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injections at Weeks 0, 4, and 12
Study NCT00801944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral
Study NCT00801944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT04273815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
Study NCT04273815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
Study NCT03477162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given to patients prior to surgery.
Study NCT03628443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroblast Growth Factor 23
Description: A sample of blood is tested for levels of fibroblast growth factor 23
Study NCT00226252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instruction Only
Description: Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
Study NCT00226252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instruction and Feedback
Description: Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
Study NCT04135547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-osseous access vs. intra-venous access
Description: EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
Study NCT04135547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intra-osseous access vs. intra-venous access
Description: EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
Study NCT04064073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR 1000mg, Tablets, Oral, BID for 7 days
Study NCT04064073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001+Metformin IR
Description: Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
Study NCT00719147 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
Study NCT00719147 — intervention group
Intervention type: OTHER
Intervention: Functional Status and Symptom Questionnaire
Description: Questionnaire
Study NCT00169377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Stimulator on followed by off
Study NCT00169377 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation
Description: Stimulator on followed by off
Study NCT00169377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No stimulation
Description: Stimulator off followed by on
Study NCT00169377 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: Stimulator off followed by on
Study NCT02656329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iobenguane I -123 Injection
Description: Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Study NCT02656329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
Study NCT02656329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid blocking
Description: Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
Study NCT02656329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: All participants allocated to the SoC (control) group underwent ICD implantation.
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 3D Laser Scanning of the Head
Description: Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Measurements and Digital Photo's of the head, neck and Mouth
Description: Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Exam of the Tongue
Description: The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Laser Scanning of the Head
Description: Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurements and Digital Photo's of the head, neck and Mouth
Description: Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
Study NCT01630694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Exam of the Tongue
Description: The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
Study NCT03767582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation (SBRT)
Description: SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
Study NCT03767582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
Study NCT03767582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCR2/CCR5 dual antagonist
Description: CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
Study NCT03767582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX
Description: Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
Study NCT04222361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI
Description: Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
Study NCT04512131 — intervention group
Intervention type: PROCEDURE
Intervention: dialysis mode
Description: intermittent hemodialysis or continuous renal replacement therapy
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1; Cohort 1
Description: On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1; Cohort 2
Description: For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Part 2; Stage 1
Description: Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2; Stage 1
Description: Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Part 2, Stage 2
Description: Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
Study NCT01445587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, Stage 2
Description: Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
Study NCT02019303 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA and Core biopsy
Description: Both procedures will be performed on the same lymph node
Study NCT03534128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the effect of cues on virtual spatial navigation using a virtual district
Description: Evaluation of the effect of cues on virtual spatial navigation using a virtual district
Study NCT04973787 — intervention group
Intervention type: BIOLOGICAL
Intervention: biological disease-modifying antirheumatic drugs (bDMARDs)
Description: bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
Study NCT01603680 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow
Description: Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
Study NCT03184038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Undergo assessment of neurocognitive function
Study NCT03184038 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT01603680 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non circumferential spread in ultrasound-guided median and ulnar nerves block
Description: Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass